Gender-specific associations between insulin resistance, hypertension, and markers of inflammation among adult Saudis with and without diabetes mellitus type 2

Advances in Medical Sciences

Volumn 55, Issue 2, 2010, Pages 179-185

  Al Daghri, N M ^a   Al Attas, O S ^a   Alokail, M S ^a   Alkharfy, K M ^b   Shaik, N A ^a   Draz, H M ^a   Bamakhramah, A ^a   Sabico, S L B ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

CRP; Cytokines; Diabetes mellitus type 2; IL 6; TNF

Indexed keywords

ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLUCOSE; INTERLEUKIN 6; LIPID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; SAUDI ARABIA; SEX DIFFERENCE;

EID: 78650431144     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-010-0052-1     Document Type: Article

References (43)

1. Nayak BS, Roberts L. Relationship between inflammatory markers, metabolic and anthropometric variables in the Caribbean type 2 diabetic patients with and without microvascular complications. J Inflamm (Lond). 2006 Dec 22;3:17.
2. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev. 2003 Jun;24(3):278-301.
3. Pickup JC Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004 Mar;27(3):813-23.
4. Kimberly MM, Cooper GR, Myers GL. An Overview of Inflammatory Markers in Type 2 Diabetes from the Perspective of the Clinical Chemist. Diabetes Technol Ther. 2006 Feb;8(1):37-44.
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001 Jul 18;286(3):327-34.
6. Souza JR, Oliveira RT, Heloisa M, Blotta SL, Coelho OR. Serum Levels of Interleukin-6 (IL-6), Interleukin-18 (IL-18) and C - reactive protein (CRP) in Patients with Type-2 Diabetes and Acute Coronary Syndrome without ST-Segment Elevation. Arq Bras Cardiol. 2008 Feb;90(2):86-90.
7. Qi L, van Dam RM, Meigs JB, Manson JE, Hunter D, Hu FB. Genetic variation in IL-6 gene and type 2 diabetes: Tagging-SNP haplotype analysis in large-scale case- control study and meta-analysis. Hum Mol Genet. 2006 Jun 1;15(11):1914-20.
8. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther. 2006;8 Suppl 2:S3.
9. Joshi SV, Tambwekar SR, Khadalia K, Dhar HL. Role of inflammatory marker interleukin 6 (IL-6) and insulin in diabetes and diabetic neuropathy. Bombay Hosp J. 2008;50(3):466-71.
10. Kim KI, Lee JH, Chang HJ, Cho YS, Youn TJ, Chung WY, Chae IH, Choi DJ, Park KU, Kim CH. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J. 2008 Feb;72(2):293-8.
11. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004 Jun 14;90(12):2312-6.
12. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000 Mar 23;342(12):836-43. (Pubitemid 30165206)
13. Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J, Ricart W. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J Clin Endocrinol Metab. 2001 Mar;86(3):1154-9.
14. Andreozzi F, Laratta E, Cardellini M, Marini MA, Lauro R, Hribal ML, Perticone F, Sesti G. Plasma Interleukin-6 Levels Are Independently Associated With Insulin Secretion in a Cohort of Italian-Caucasian Nondiabetic Subjects. Diabetes. 2006 Jul;55(7):2021-4.
15. Thorand B, Baumert J, Kolb H, Meisinger C, Chambless L, Koenig W, Herder C. Sex differences in the prediction of type 2 diabetes by inflammatory markers: Results from the MONICA/KORA Augsburg case-cohort study, 1984- 2002. Diabetes Care. 2007 Apr;30(4):854-60.
16. Khera A, Darren K, McGuire, Murphy SA, Stanek GH, Das SR, Vongpatanasin W, Wians HF, Grundy SM, Lemos JA. Race and gender differences in C-reactive protein levels. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, Wians FH Jr, Grundy SM, de Lemos JA. J Am Coll Cardiol. 2005 Aug 2;46(3):464-9.
17. Chapman BP, Khan A, Harper M, Stockman D, Fiscella K, Walton J, Duberstein P, Talbot N, Lyness JM, Moynihan J. Gender, race/ethnicity, personality and interleukin-6 in urban primary care patients. Brain Behav Immun. 2009 Jul;23(5):636-42.
18. Pfeiffer A, Janott J, Möhlig M, Ristow M, Rochlitz H, Busch K, Schatz H, Schifferdecker E. Circulating tumor necrosis factor alpha is elevated in male but not female patients with type II diabetes mellitus. Horm Metab Res. 1997 Mar;29(3):111-4.
19. Elhaad TA, Al-Amoudi AA, Alzaharani AS. Epemiology, clinical and complications of diabetes in Saudi Arabia. Ann Saudi Med. 2007 Jul-Aug;27(4):241-50.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.
21. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M. Prevalence of Insulin Resistance in Metabolic Disorders, The Bruneck Study. Diabetes. 1998 Oct;47(10):1643-9.
22. Rathmann W, Haastert B, Icks A, Giani G, Holle R, Koenig W, Löwel H, Meisinger C. Prevalence of the metabolic syndrome in the elderly population according to IDF, WHO, and NCEP definitions and associations with C-reactive protein: The KORA Survey 2000. Diabetes Care. 2006 Feb;29(2):461.
23. Maurel S, Hamon B, Taillandier J, Rudant E, Bonhomme-Faivre L, Trivalle C. Prognostic value of serum interleukin-6 (IL-6) levels in long term care. Arch Gerontol Geriatr. 2007 Jul-Aug;45(1):65-71.
24. Lele RD, Joshi SR, Gupte A. Association of adipocytokines (leptin, adiponectin TNF-alpha), insulin and proinsulin with diabetes-the Mumbai Obesity Project [MOP]. J Assoc Physicians India. 2006 Sep;54:689-96.
25. Pottratz ST, Bellido T, Mocharis H, Crabb D, Manolagas SC. 17 beta-Estradiol inhibits expression of human interleukin-6 promoter-reporter constructs by a receptordependent mechanism. J Clin Invest. 1994 Mar;93(3):944-50.
26. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA. Interleukin-6 and tumor necrosis factor-a are not increased in patients with Type 2 diabetes: Evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia. 2004 Jun;47(6):1029-37.
27. Kado S, Nagase T, Nagata N. Circulating levels of interleukin-6, its soluble receptor and interleukin-6/ interleukin-6 receptor complexes in patients with type 2 diabetes mellitus. Acta Diabetol. 1999 Jun;36(1-2):67-72.
28. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF. Inflammatory cytokines and the risk to develop type 2 diabetes: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)- Potsdam Study. Diabetes. 2003 Mar;52(3):812-7.
29. Mooney RA. Counterpoint: Interleukin-6 does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol. 2007 Feb;102(2):816-8
30. Pedersen BK, Febbraio MA. Interleukin-6 does have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol. 2007 Feb;102(2):814-6.
31. M?ller S, Martin S, Koenig W, Hanifi-Moghaddam P, Rathmann W, Haastert B, Giani G, Illig T, Thorand B, Kolb H. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acutephase proteins but not TNF-a or its receptors. Diabetologia. 2002 Jun;45(6):805-12.
32. Pickup JC, Chusney GD, Thomas SM, Burt D. Plasma interleukin- 6, tumour necrosis factor alpha and blood cytokine production in type 2 diabetes. Life Sci. 2000 Jun 8;67(3):291-300.
33. Stith RD, Luo J. Endocrine and carbohydrate responses to interleukin-6 in vivo. Circ Shock. 1994 Dec;44(4):210-5.
34. Klover PJ, Zimmers TA, Koniaris LG, Mooney RA. Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes. 2003 Nov;52(11):2784-9.
35. Straub RH, Hense HW, Andus T, Schölmerich J, Riegger GA, Schunkert H. Hormone replacement therapy and interrelation between serum interleukin-6 and body mass index in postmenopausal women: A population-based study. J Clin Endocrinol Metab. 2000 Mar;85(3):1340-4.
36. Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA. Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism. 2003 Jul;52(7):939-44.
37. van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R, Romijn H, de Kam M, Schoemaker R, Burggraaf K, Cohen A. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. Br J Clin Pharmacol. 2006 Oct;62(4):391-402.
38. Zinman B, Hanley AJ, Harris SB, Kwan J, Fantus IG. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab. 1999 Jan;84(1):272-8.
39. An J, Ribeiro RC, Webb P, et al. Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators. Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15161-6.
40. Ahonen T, Saltevo J, Laakso M, Kautiainen H, Kumpusalo E, Vanhala M. Gender differences relating to metabolic syndrome and proinflammation in Finnish subjects with elevated blood pressure. Mediators Inflamm. 2009;2009:959281.
41. Snijder MB, Dekker JM, Visser M Stehouwer CD, Yudkin JS, Bouter LM, Heine RJ, Nijpels G, Seidell JC. Prospective relation of C-reactive protein with type 2 diabetes. Diabetes Care. 2003 May;26(5):1656-7.
42. Doi Y, Kiyohara Y, Kubo M, Ninomiya T, Wakugawa Y, Yonemoto K, Iwase M, Iida M. Elevated C-reactive protein is a predictor of the development of diabetes in a general Japanese population: The Hisayama study. Diabetes Care. 2005 Oct;28(10):2497-500.
43. Han TS, Sattar N, Williams K, Gonzalez- Villalpando C, Lean ME, Haffner SM. Prospective study of C-reactive protein in relation to the development of diabetes and metabolic syndrome in the Mexico City Diabetes Study. Diabetes Care. 2002 Nov;25(11):2016-21.